Literature DB >> 22836386

Impact of the AT(2) receptor agonist C21 on blood pressure and beyond.

Sébastien Foulquier1, U Muscha Steckelings, Thomas Unger.   

Abstract

It is now widely accepted that the angiotensin AT(2) receptor (AT(2)R) plays an important protective role during pathophysiologic conditions, acting as a repair system. The development of the first selective nonpeptide AT(2)R agonist C21 accelerated our understanding of AT(2)R-mediated protective signaling and actions. This article reviews the impact of C21 on blood pressure in normotensive and hypertensive animal models. Although C21 does not act as a classical antihypertensive drug, it could be useful in preventing hypertension-induced vascular and other end organ damages via anti-apoptotic, anti-fibrotic and anti-inflammatory actions. In particular, a strong body of evidence started to emerge around its anti-inflammatory feature. This property should be further investigated for potential clinical indications in cardiovascular diseases and beyond.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836386     DOI: 10.1007/s11906-012-0291-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  43 in total

Review 1.  An ATIPical family of angiotensin II AT2 receptor-interacting proteins.

Authors:  Sylvie Rodrigues-Ferreira; Clara Nahmias
Journal:  Trends Endocrinol Metab       Date:  2010-11       Impact factor: 12.015

2.  Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury.

Authors:  Caterina Curato; Svetlana Slavic; Jun Dong; Anna Skorska; Wassim Altarche-Xifró; Kapka Miteva; Elena Kaschina; Andreas Thiel; Hans Imboden; Jianan Wang; Ulrike Steckelings; Gustav Steinhoff; Thomas Unger; Jun Li
Journal:  J Immunol       Date:  2010-10-08       Impact factor: 5.422

3.  Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage.

Authors:  Paolo Gelosa; Alice Pignieri; Lars Fändriks; Marc de Gasparo; Anders Hallberg; Cristina Banfi; Laura Castiglioni; Lucia Turolo; Uliano Guerrini; Elena Tremoli; Luigi Sironi
Journal:  J Hypertens       Date:  2009-12       Impact factor: 4.844

4.  Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR.

Authors:  R M Touyz; D Endemann; G He; J S Li; E L Schiffrin
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

Review 5.  Emerging drugs which target the renin-angiotensin-aldosterone system.

Authors:  Ulrike Muscha Steckelings; Ludovit Paulis; Thomas Unger; Michael Bader
Journal:  Expert Opin Emerg Drugs       Date:  2011-09-12       Impact factor: 4.191

Review 6.  The renin-angiotensin system, bone marrow and progenitor cells.

Authors:  Matej Durik; Bruno Sevá Pessôa; Anton J M Roks
Journal:  Clin Sci (Lond)       Date:  2012-08-01       Impact factor: 6.124

7.  Constrictor and dilator effects of angiotensin II on cerebral arterioles.

Authors:  Jean-Martin Vincent; Yiu Wa Kwan; Siu Lung Chan; Caroline Perrin-Sarrado; Jeffrey Atkinson; Jean-Marc Chillon
Journal:  Stroke       Date:  2005-11-03       Impact factor: 7.914

8.  Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats.

Authors:  S Bosnyak; I K Welungoda; A Hallberg; M Alterman; R E Widdop; E S Jones
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

9.  AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR.

Authors:  Xiao C Li; Robert E Widdop
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

10.  Deletion of angiotensin II type 2 receptor attenuates protective effects of bone marrow stromal cell treatment on ischemia-reperfusion brain injury in mice.

Authors:  Jun Iwanami; Masaki Mogi; Jian-Mei Li; Kana Tsukuda; Li-Juan Min; Akiko Sakata; Teppei Fujita; Masaru Iwai; Masatsugu Horiuchi
Journal:  Stroke       Date:  2008-07-10       Impact factor: 7.914

View more
  15 in total

Review 1.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

Review 2.  Coronary microvascular disease as an early culprit in the pathophysiology of diabetes and metabolic syndrome.

Authors:  Hicham Labazi; Aaron J Trask
Journal:  Pharmacol Res       Date:  2017-07-09       Impact factor: 7.658

Review 3.  AT2 receptor activities and pathophysiological implications.

Authors:  Luis C Matavelli; Helmy M Siragy
Journal:  J Cardiovasc Pharmacol       Date:  2015-03       Impact factor: 3.105

Review 4.  Update on the angiotensin AT(2) receptor.

Authors:  Claudia A McCarthy; Robert E Widdop; Kate M Denton; Emma S Jones
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

5.  Perspective: A tale of two receptors.

Authors:  Sébastien Foulquier; Ulrike Muscha Steckelings; Thomas Unger
Journal:  Nature       Date:  2013-01-31       Impact factor: 49.962

6.  As drug target reemerges, the question is to block or stimulate it.

Authors:  Cassandra Willyard
Journal:  Nat Med       Date:  2014-03       Impact factor: 53.440

Review 7.  Update on angiotensin AT2 receptors.

Authors:  Robert M Carey
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-03       Impact factor: 2.894

8.  Long-term treatment of spontaneously hypertensive rats with PD123319 and electrophysiological remodeling of left ventricular myocardium.

Authors:  Xiao Ying; Guan Kai-Pan; Long Wei-Qing; Peng Long-Yun; Wu De-Xi; Huang Zhi-Bin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-14       Impact factor: 3.000

9.  AT2R autoantibodies block angiotensin II and AT1R autoantibody-induced vasoconstriction.

Authors:  Campbell Liles; Hongliang Li; Vineet Veitla; Jonathan T Liles; Taylor A Murphy; Madeleine W Cunningham; Xichun Yu; David C Kem
Journal:  Hypertension       Date:  2015-08-10       Impact factor: 10.190

Review 10.  New Molecules for Treating Resistant Hypertension: a Clinical Perspective.

Authors:  Omar Azzam; Marcio G Kiuchi; Jan K Ho; Vance B Matthews; Leslie Marisol Lugo Gavidia; Janis M Nolde; Revathy Carnagarin; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2019-09-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.